Belgian BLINCYTO study | FAIR Healthdata

Primary tabs

Default group image

Amgen

License

License Not Specified

Other Access

The information on this page (the dataset metadata) is also available in these formats.

via the DKAN API

Belgian BLINCYTO study

Real world data collection on the efficacy and drug usage of BLINCYTO (blinatumomab).

Data and Resources

Belgian BLINCYTO studyjson Download

Field	Value
Publisher	Amgen
Modified	2020-09-28
Release Date	2019-08-07
Identifier	dec0da0b-2d26-4298-98c5-772998fef230
License	License Not Specified
Public Access Level	Public

Protocol

Protocol
Full title of the project	Belgian BLINCYTO study

Sponsor(s)

Primary organization that oversees implementation of study and is responsible for data analysis.
Name of organisation	Amgen

General information

General information
Project description	Real world data collection on the efficacy and drug usage of BLINCYTO (blinatumomab).

Medical condition or disease under investigation
Medical condition(s) being investigated	Philadelphia chromosome negative relapsed or refractory B-precursor acute lymphoblastic leukemia (ALL)
Medical condition in easily understood language	Type of blood cancer that has not responded to or has relapsed after a first treatment line of chemotherapy

Therapeutic area
Disease	Cancer

Objective of the project
Main objective of the project	To capture if a patient treated with BLINCYTO in real life has achieved a complete remission (defined as <5% blasts in the bone marrow) after an induction therapy and if not, to capture the number of BLINCYTO vials used.